This Evithrom market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historical period can be attributed to the rise of minimally invasive surgical techniques, the increasing demand for natural or bio-based surgical sealants, a focus on reducing postoperative complications, and the widespread adoption of fibrin sealants.
Growth during the market's forecast will be driven by the rising number of surgical procedures, growing demand for advanced wound care and surgical solutions, an increase in spinal and sports-related injuries, and the higher prevalence of chronic diseases. Key trends during the forecast period include advancements in fibrin sealants technology, the adoption of minimally invasive innovations in hemostasis and tissue sealing agents, medical technology developments, and strategic partnerships between biotechnology companies.
The increasing number of surgical procedures is expected to drive the growth of the evithrom market in the coming years. Surgical procedures involve medical interventions that require physical alteration or manipulation of tissues and organs. This rise in surgical procedures is mainly attributed to advances in medical technology, which have made surgeries safer and more efficient, as well as the increasing prevalence of chronic diseases, which necessitate more surgical treatments. Evithrom is used during surgical procedures to control bleeding by promoting clot formation and supporting hemostasis, especially in high-risk surgeries such as cardiovascular and orthopedic procedures. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS) reported that liposuction remained the most common surgical procedure in 2023, with over 2.2 million performed, while face and head surgeries grew significantly by 19.6%, totaling more than 6.5 million. Hence, the rising number of surgical procedures is a key factor driving the growth of the evithrom market.
The growing focus on personalized medicine is also expected to propel the growth of the evithrom market. Personalized medicine tailors treatment strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve optimal outcomes. This trend is fueled by advancements in genomic technologies, better understanding of molecular biology, greater availability of precision diagnostic tools, and increased demand for targeted therapies that enhance patient outcomes while minimizing side effects. Evithrom supports personalized medicine by providing precise hemostatic management, tailored to each patient’s needs, ensuring effective control of bleeding during surgical procedures. For instance, in 2023, the Personalized Medicine Coalition reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, a rise from at least 25% in the previous eight years. Thus, the rise in personalized medicine is driving the growth of the evithrom market.
The growing incidence of spinal-related injuries is expected to fuel the growth of the evithrom market in the future. Spinal-related injuries involve damage to the spinal cord, vertebrae, discs, or surrounding tissues due to accidents, falls, or medical conditions. The rise in spinal injuries is linked to higher rates of road traffic accidents and an aging population more susceptible to conditions such as osteoporosis, which increase fracture risk. Evithrom is used during spinal surgeries to control bleeding by promoting clot formation at the surgical site, helping manage blood loss during procedures such as spinal fusion or decompression. For example, in October 2024, the Congressionally Directed Medical Research Programs reported that around 300,000 people in the U.S. are living with spinal cord injuries (SCI), with more than 17,000 new cases each year, and the numbers continue to rise. Therefore, the increasing prevalence of spinal injuries is contributing to the growth of the evithrom market.
The key company operating in the evithrom market is Johnson & Johnson Inc.
North America was the largest region in the evithrom market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in evithrom report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the evithrom market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Evithrom is a topical hemostatic agent made from human thrombin and fibrinogen, designed to control bleeding during surgical procedures. It is used in a variety of surgeries, including cardiovascular and orthopedic procedures, to facilitate blood clot formation and prevent excessive bleeding.
The primary indications for evithrom include surgical hemostasis and trauma care. Surgical hemostasis refers to the techniques and methods used during surgeries to stop bleeding and close blood vessels. It is available in formulations containing bovine thrombin, human thrombin, and recombinant thrombin, and is distributed through hospitals, clinics, diagnostic centers, and online pharmacies.
The evithrom market research report is one of a series of new reports that provides evithrom market statistics, including evithrom industry global market size, regional shares, competitors with an evithrom market share, detailed evithrom market segments, market trends and opportunities, and any further data you may need to thrive in the evithrom industry. This evithrom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The evithrom market consists of sales of products including albumin, immunoglobulins, prothrombin complex concentrates, C1 esterase inhibitors, and fibrin sealants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historical period can be attributed to the rise of minimally invasive surgical techniques, the increasing demand for natural or bio-based surgical sealants, a focus on reducing postoperative complications, and the widespread adoption of fibrin sealants.
Growth during the market's forecast will be driven by the rising number of surgical procedures, growing demand for advanced wound care and surgical solutions, an increase in spinal and sports-related injuries, and the higher prevalence of chronic diseases. Key trends during the forecast period include advancements in fibrin sealants technology, the adoption of minimally invasive innovations in hemostasis and tissue sealing agents, medical technology developments, and strategic partnerships between biotechnology companies.
The increasing number of surgical procedures is expected to drive the growth of the evithrom market in the coming years. Surgical procedures involve medical interventions that require physical alteration or manipulation of tissues and organs. This rise in surgical procedures is mainly attributed to advances in medical technology, which have made surgeries safer and more efficient, as well as the increasing prevalence of chronic diseases, which necessitate more surgical treatments. Evithrom is used during surgical procedures to control bleeding by promoting clot formation and supporting hemostasis, especially in high-risk surgeries such as cardiovascular and orthopedic procedures. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS) reported that liposuction remained the most common surgical procedure in 2023, with over 2.2 million performed, while face and head surgeries grew significantly by 19.6%, totaling more than 6.5 million. Hence, the rising number of surgical procedures is a key factor driving the growth of the evithrom market.
The growing focus on personalized medicine is also expected to propel the growth of the evithrom market. Personalized medicine tailors treatment strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve optimal outcomes. This trend is fueled by advancements in genomic technologies, better understanding of molecular biology, greater availability of precision diagnostic tools, and increased demand for targeted therapies that enhance patient outcomes while minimizing side effects. Evithrom supports personalized medicine by providing precise hemostatic management, tailored to each patient’s needs, ensuring effective control of bleeding during surgical procedures. For instance, in 2023, the Personalized Medicine Coalition reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, a rise from at least 25% in the previous eight years. Thus, the rise in personalized medicine is driving the growth of the evithrom market.
The growing incidence of spinal-related injuries is expected to fuel the growth of the evithrom market in the future. Spinal-related injuries involve damage to the spinal cord, vertebrae, discs, or surrounding tissues due to accidents, falls, or medical conditions. The rise in spinal injuries is linked to higher rates of road traffic accidents and an aging population more susceptible to conditions such as osteoporosis, which increase fracture risk. Evithrom is used during spinal surgeries to control bleeding by promoting clot formation at the surgical site, helping manage blood loss during procedures such as spinal fusion or decompression. For example, in October 2024, the Congressionally Directed Medical Research Programs reported that around 300,000 people in the U.S. are living with spinal cord injuries (SCI), with more than 17,000 new cases each year, and the numbers continue to rise. Therefore, the increasing prevalence of spinal injuries is contributing to the growth of the evithrom market.
The key company operating in the evithrom market is Johnson & Johnson Inc.
North America was the largest region in the evithrom market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in evithrom report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the evithrom market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Evithrom is a topical hemostatic agent made from human thrombin and fibrinogen, designed to control bleeding during surgical procedures. It is used in a variety of surgeries, including cardiovascular and orthopedic procedures, to facilitate blood clot formation and prevent excessive bleeding.
The primary indications for evithrom include surgical hemostasis and trauma care. Surgical hemostasis refers to the techniques and methods used during surgeries to stop bleeding and close blood vessels. It is available in formulations containing bovine thrombin, human thrombin, and recombinant thrombin, and is distributed through hospitals, clinics, diagnostic centers, and online pharmacies.
The evithrom market research report is one of a series of new reports that provides evithrom market statistics, including evithrom industry global market size, regional shares, competitors with an evithrom market share, detailed evithrom market segments, market trends and opportunities, and any further data you may need to thrive in the evithrom industry. This evithrom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The evithrom market consists of sales of products including albumin, immunoglobulins, prothrombin complex concentrates, C1 esterase inhibitors, and fibrin sealants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Evithrom Market Characteristics4. Evithrom Market Trends and Strategies5. Evithrom Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Evithrom Pricing Analysis & Forecasts30. Global Evithrom Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Evithrom Market32. Recent Developments in the Evithrom Market
3. Evithrom Market Biologic Drug Characteristics
6. Global Evithrom Growth Analysis and Strategic Analysis Framework
8. Evithrom Market Segmentation
9. Global Evithrom Epidemiology of Clinical Indications
10. Evithrom Market Regional and Country Analysis
11. Asia-Pacific Evithrom Market
12. China Evithrom Market
13. India Evithrom Market
14. Japan Evithrom Market
15. Australia Evithrom Market
16. South Korea Evithrom Market
17. Western Europe Evithrom Market
18. UK Evithrom Market
19. Germany Evithrom Market
20. France Evithrom Market
21. Eastern Europe Evithrom Market
22. North America Evithrom Market
23. USA Evithrom Market
24. Canada Evithrom Market
25. South America Evithrom Market
26. Middle East Evithrom Market
27. Africa Evithrom Market
28. Evithrom Market Competitive Landscape and Company Profiles
29. Global Evithrom Market Pipeline Analysis
33. Evithrom Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Evithrom Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on evithrom market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for evithrom? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The evithrom market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Surgical Hemostasis; Trauma Care2) by Formulation: Bovine Thrombin; Human Thrombin; Recombinant Thrombin
3) by Distribution Channel: Hospitals; Clinics and Diagnostic Centers; Online Pharmacies
Key Companies Mentioned: Johnson & Johnson Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Johnson & Johnson Inc.
